Clinical

Dataset Information

0

Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab


ABSTRACT: Prometheus’s Onco dX assay platform provides technological breakthrough for immunoassay by obtaining a level of sensitivity down to single tumor cells without compromising specificity. This allows assessment of multiple TKI treatment targets, their activation status, as well as down stream signaling proteins using very tiny amount of tissue that can be obtained by FNA or CTCs. We planned this study to explore biomarkers predictive of clinical response to cetuximab-based treatment in metastatic colorectal cancer using the Prometheus Platform. We will also elucidate signal transduction pathway attributable to cetuximab resistance, monitor changes in the RTK activation status during cetuximab treatment using circulating tumor cells and analyze correlation between the quantity of circulating tumor cells and treatment response to cetuximab.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2158250 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2014-04-01 | E-GEOD-56386 | biostudies-arrayexpress
2014-04-01 | GSE56386 | GEO
2012-07-13 | E-GEOD-23428 | biostudies-arrayexpress
2020-03-23 | GSE143279 | GEO
2018-12-01 | GSE114928 | GEO
2017-03-02 | GSE63916 | GEO
2016-07-17 | E-GEOD-71210 | biostudies-arrayexpress
2016-07-17 | GSE71210 | GEO
2024-09-02 | BIOMD0000001042 | BioModels
2012-07-14 | GSE23428 | GEO